<DOC>
	<DOCNO>NCT00759070</DOCNO>
	<brief_summary>This study open-label , randomize , pilot comparison effect either lopinavir/ritonavir efavirenz combination tenofovir plus emtricitabine cholesterol metabolism , mitochondrial function immune response 50 naive HIV patient 48 week .</brief_summary>
	<brief_title>Effects 2 Initial Standard Antiretroviral Combinations Therapies Lipid Metabolism</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Chronic HIV1 infection Age 18 Antiretroviralnaive Criteria antiretroviral therapy accordance current guideline Plasma LDLcholesterol 190 mg/dL Not receive lipidlowering agent Written inform consent Use phytosterolenriched food previous month . Pregnancy breastfeed Cardiovascular disease Secondary Hypercholesterolemia Plasma creatinine 1,2 mg/dL ) Aminotransferases 5 time ULN Current treatment hepatitis C coinfection Diabetes mellitus ( fast glycemia &gt; 124 mg/dL ) Illegal drug use alcohol abuse Active AIDSdefining opportunistic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Treatment Na√Øve</keyword>
</DOC>